Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho to Require More Data Electronically on Clinical Trials
January 17, 2011
- WAKAMOTO Launches Vitreous Surgery Adjuvant MaQaid
January 17, 2011
- Tasigna Approved in 1st-Line Therapy for CML: Novartis
January 17, 2011
- Perpetuation of New Premium Top-Priority Issue in 2011: FPMAJ President Shoda
January 17, 2011
- FDA Grants Supplemental Approval for Roche's Actemra
January 17, 2011
- Bayer, J&J Apply for Rivaroxaban for SPAF in the US, Europe
January 17, 2011
- MINCLEA for Inhibiting GI Peristalsis: ASKA, Nihon Pharm.
January 17, 2011
- Ex-Drug Company Employees Accounts for 21 at PMDA
January 17, 2011
- Top-Leaders Stress Importance of Renovation in New Year's Addresses
January 17, 2011
- Mr Hasegawa to Lead Both KEIZAI DOYUKAI, Takeda
January 17, 2011
- BI Group to Inaugurate New Business Structure in Japan
January 17, 2011
- IBL to Develop Antibody Drugs Using Transgenic Silkworm
January 17, 2011
- Blopress Remains No. 1 for 7th Term in a Row: Domestic Drug Sales Ranking
January 17, 2011
- Mizuho Securities Lists Halaven, KW-0761 as Promising Anticancer Agents
January 17, 2011
- Pharma Industry Must Drive Nation's Economic Growth: Mr Matsuda
January 17, 2011
- Bayer, Regeneron Report Positive Results from 2 Studies on VEGF Trap-Eye
January 17, 2011
- Mr Matsutani Calls For Closer Cooperation with Makers to Settle Prices Quickly
January 17, 2011
- SymBio Starts PII Trial of Transdermal Antiemetic in Japan
January 17, 2011
- Morishita Jintan Merges Jintan Tech
January 17, 2011
- Prospects for Simultaneous Global Development: 3
January 17, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…